Journal
BIOMARKERS IN MEDICINE
Volume 10, Issue 1, Pages 35-49Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm.15.107
Keywords
alpha-synuclein; cerebrospinal fluid biomarkers; cognitive impairment; disease progression; early diagnosis; motor symptoms; parkinsonisms; Parkinson's disease; prognosis
Categories
Ask authors/readers for more resources
Since diagnosis of Parkinson's disease (PD) is mostly based on clinical criteria, it is almost impossible to formulate an early diagnosis, as well as a timely differential diagnosis versus other parkinsonisms. A great effort in searching reliable biomarkers both for early diagnosis and prognosis in PD is currently ongoing. Cerebrospinal fluid has been widely investigated as potential source for such biomarkers, with particular emphasis on -synuclein (-syn) species. We reviewed all the clinical studies carried out so far on cerebrospinal fluid quantification of -syn species in PD. Current evidence supports the value of total and oligomeric -syn in PD diagnosis and in the differential diagnosis of PD and other parkinsonisms. Conversely, the role of -syn species in PD prognosis remains unsatisfactory.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available